On Topic Virtual Roundtable: “BTK Battle” – Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies

On Topic Virtual Roundtable: “BTK Battle” – Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies is organized by Bio Ascend LLC.

Release Date: January 31, 2023
Expiration Date: January 31, 2024

Learning Objectives:
After participating in this activity, participants should be better able to:
• Evaluate the safety and efficacy of currently approved BTK inhibitors for patients with hematologic malignancies, including CLL/SLL, lymphoma, and Waldenström’s macroglobulinemia 
• Review clinical trial results of emerging BTK-inhibitor-based strategies that are being investigated in patients with hematologic malignancies
• Compare and contrast the safety and efficacy of BTK inhibitors in order to properly select and sequence this class of agents in patients with newly diagnosed and relapsed/refractory hematologic malignancies

Topics:
• Module 1: Ibrutinib for Hematologic Malignancies
• Module 2: Acalabrutinib for Hematologic Malignancies
• Module 3: Zanubrutinib for Hematologic Malignancies
• Module 4: Emerging BTK Inhibitors
• Module 5: Experts Debate Optimal Selection and Sequencing Strategies

1.0 AMA PRA Category 1 Credit™